New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer
- PMID: 26861657
- DOI: 10.1007/s11912-016-0504-2
New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer
Abstract
Recently, colorectal cancer (CRC) subtyping consortium identified four consensus molecular subtypes (CMS1-4). CMS1 is enriched for deficient mismatch repair (dMMR) and BRAF (V600E) tumors. Intriguingly, this subtype has better relapse-free survival but worse overall survival after relapse compared with the other subtypes. Growing evidence is accumulating on the benefit of specific therapeutic strategies such as immune checkpoint inhibition therapy in dMMR tumors and mitogen-activated protein kinase (MAPK) pathway targeted therapy in tumors harboring BRAF (V600E) mutation. After reviewing dMMR prognostic value, immune checkpoints as major targets for dMMR carcinomas will be highlighted. Following, BRAF (V600E) prognostic impact will be reviewed and therapeutic strategies with the combination of cytotoxic agents and especially the combinations of BRAF and MAPK inhibitors will be discussed.
Keywords: BRAF mutation; Immune checkpoint; Microsatellite instability; PD-1; PD-L1.
Similar articles
-
[DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].Bull Cancer. 2015 Jun;102(6 Suppl 1):S72-81. doi: 10.1016/S0007-4551(15)31220-0. Bull Cancer. 2015. PMID: 26118880 Review. French.
-
Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.World J Gastroenterol. 2015 Jan 21;21(3):926-34. doi: 10.3748/wjg.v21.i3.926. World J Gastroenterol. 2015. PMID: 25624727 Free PMC article.
-
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?Curr Treat Options Oncol. 2017 Feb;18(2):9. doi: 10.1007/s11864-017-0453-5. Curr Treat Options Oncol. 2017. PMID: 28214977 Review.
-
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.Discov Med. 2016 May;21(117):341-7. Discov Med. 2016. PMID: 27355330 Review.
-
Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.Clin Transl Oncol. 2018 Nov;20(11):1422-1429. doi: 10.1007/s12094-018-1874-8. Epub 2018 May 25. Clin Transl Oncol. 2018. PMID: 29802524
Cited by
-
Outcomes of Chemotherapy for Microsatellite Instable-High Metastatic Colorectal Cancers.JCO Precis Oncol. 2018 Jul 16;2:PO.17.00253. doi: 10.1200/PO.17.00253. eCollection 2018. JCO Precis Oncol. 2018. PMID: 32913995 Free PMC article.
-
CT-Based Radiomics Signature: A Potential Biomarker for Predicting Postoperative Recurrence Risk in Stage II Colorectal Cancer.Front Oncol. 2021 Mar 19;11:644933. doi: 10.3389/fonc.2021.644933. eCollection 2021. Front Oncol. 2021. PMID: 33816297 Free PMC article.
-
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.Int J Environ Res Public Health. 2016 Sep 8;13(9):892. doi: 10.3390/ijerph13090892. Int J Environ Res Public Health. 2016. PMID: 27618077 Free PMC article. Review.
-
Deep Phenotypic Characterisation of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream).Cancers (Basel). 2021 Dec 20;13(24):6386. doi: 10.3390/cancers13246386. Cancers (Basel). 2021. PMID: 34945008 Free PMC article.
-
Back to the Colorectal Cancer Consensus Molecular Subtype Future.Curr Gastroenterol Rep. 2019 Jan 30;21(2):5. doi: 10.1007/s11894-019-0674-9. Curr Gastroenterol Rep. 2019. PMID: 30701321 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials